Qurexa Logo
Qurexa

Trust. Care. Deliver.

Back to Blog & Insights
Technology

100 million readings from a single blood sample, and 80,000 samples to get through

Qurexa Editorial Team19 October 20266 min read 0 0
100 million readings from a single blood sample, and 80,000 samples to get through

What happened

On Monday 19 October 2026, a British company called IMU Biosciences announced a project with UK Biobank to build what the partners describe as the most detailed large-scale picture of the human immune system yet attempted. The first phase will take 80,000 blood samples that UK Biobank already holds, and analyse each one in extraordinary detail. The companies say they will generate more than 100 million immune data points from every single sample. UK Biobank is a long-running British health research project. It has followed around 500,000 volunteers over about 15 years. It already holds their genetic data, scans and images from 100,000 of them, protein markers from 54,000 of them, and a great deal of clinical and lifestyle information. What it has not had, in any depth, is a picture of the immune system. That is the layer this project is meant to add. The work is being done by four organisations together. IMU Biosciences runs the analysis using its own platform. Waters Corporation supplies the instruments that sort and read individual cells. Ultima Genomics provides the sequencing machine, its UG200. UK Biobank provides the samples and the health records they connect to. It is partly publicly backed. The project has a £1.57 million Sovereign AI grant from the UK government, through its Strategic Assets programme. Work begins in 2026. The partners say they hope to extend the work across the full 500,000-person group, though they describe that as an ambition rather than a commitment.

Why this matters

Your immune system is not one thing. It is a large collection of different cell types, in different states, changing all the time. Two people with identical genes can have very different immune systems, shaped by infections, age, stress and chance. That variation is hard to study. Measuring it properly in one person takes a lot of work. Measuring it in tens of thousands of people, in a consistent way, has mostly been out of reach. The point of doing it inside UK Biobank is that the samples come attached to decades of health records. Researchers would not just see what someone's immune system looked like. They could look at what happened to that person afterwards. Professor Naomi Allen, UK Biobank's Chief Scientist, set out what that could allow. She said scientists "will be able to study which specific immune cell changes contribute to the future risk" of conditions such as cancer, diabetes and dementia. She also said the resulting map could help find new drug targets. Dr Adam Laing, co-founder and Chief Scientific Officer at IMU Biosciences, described the collaboration as representing "an important opportunity to add a new immune dimension" to the resource. There is a practical reason this is being done at this scale, rather than in several smaller studies. Gilad Almogy, Ultima Genomics' chief executive, put it plainly: "Generating data at this scale requires a combination of throughput, quality, cost efficiency and operational execution." Measurements only work as a comparison if they are all taken the same way.

What the evidence actually says

This is an announcement about work that is starting, not a result. That distinction is worth holding on to. No findings have been published. Nothing here tells you anything new about cancer, diabetes or dementia today. What has been announced is a plan to build a dataset, some funding, and the equipment it will run on. The strength of the plan is real. UK Biobank's existing data is genuinely one of the most used health research resources in the world. The partners say more than 22,000 researchers in over 60 countries have access to it, and that it has contributed to more than 18,000 peer-reviewed papers. Adding a well-made immune layer to that is a sensible thing to do. The honest caveats are also real. The first is time. The data will be returned to UK Biobank "over time" and then made available to approved researchers through UK Biobank's existing application process. No dates for that have been given. Discoveries, if they come, come after that. The second is that the 500,000 figure being quoted in some coverage is the ambition, not the project. The committed phase is 80,000 samples. The third is that much of the detail in this announcement comes from company press releases. The figures about instruments, data points and partnerships are the partners' own descriptions of their own work. That does not make them wrong, but it is not the same as independent verification, and the republishing sites say as much themselves. One point on privacy, because people reasonably ask. UK Biobank data is de-identified, and researchers get access by application rather than by simply downloading it. That is the system this project is feeding into, not a new one.

Practical advice

There is nothing here you need to do. But there are a few sensible ways to think about it. If you are a UK Biobank participant: - Your samples were given for exactly this kind of research. This is the resource being used as intended. - If you want to check what you agreed to, or change your participation, UK Biobank has a participant section on its website covering consent and withdrawal. If you follow health news: - Treat "scientists are building a dataset" and "scientists have found something" as two very different kinds of story. This is the first. - When results do arrive, the useful questions are how many people were studied, and whether the finding has been repeated elsewhere. If you work in or are studying science: - UK Biobank access is by application and is open to researchers internationally, including from industry. The process is documented publicly. And a general point. Large British research resources like this are quietly one of the more useful things the country has built. They are worth knowing about, and worth protecting, long before any single headline comes out of them.

What to know

IMU Biosciences, UK Biobank, Waters Corporation and Ultima Genomics announced on 19 October 2026 that they will profile the immune systems of 80,000 UK Biobank participants in detail, producing more than 100 million immune data points per sample. The project has a £1.57 million Sovereign AI grant from the UK government and starts in 2026. The partners hope to extend it across UK Biobank's full group of 500,000 volunteers, but that is stated as an ambition. The data will be returned to UK Biobank over time and made available to approved researchers. No timetable for that has been published, and no findings exist yet. Much of the detail comes from the partners' own press releases, so it is best read as a credible statement of intent rather than an independently checked result. Sources: PR Newswire, "Ultima Genomics Selected for Landmark Large-Scale Immune Profiling Study with IMU Biosciences, UK Biobank and Waters Corporation", 19 October 2026, https://www.prnewswire.com/news-releases/ultima-genomics-selected-for-landmark-large-scale-immune-profiling-study-with-imu-biosciences-uk-biobank-and-waters-corporation-302912051.html; Business Wire via Stockhouse, "IMU and UK Biobank to generate the world's most detailed, large-scale picture of the human immune system", 19 October 2026, https://stockhouse.com/news/press-releases/2026/10/19/imu-and-uk-biobank-to-generate-the-world-s-most-detailed-large-scale-picture-of; UKTN, "IMU Biosciences raises £40m to change disease diagnosis", 2 June 2026, https://www.uktech.news/biotech/imu-biosciences-raises-40m-to-change-how-diseases-are-diagnosed-20260602. This article is for general information about medical research and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.

#UK Biobank#medical research#immune system#health data#genomics#British science

Related articles